CD274 and neoplasm: Despite treatment with Durvalumab resulting in a reduced risk of death in patients with PDL-1 expression on at least 25% of tumor cells, the study did not meet its primary end points of improved OS with immunotherapeutic strategies vs. chemotherapy [61].